Novo Nordisk (NVO) earnings Q2 2025
Ozempic and Wegovy boxes made by Novo Nordisk at a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Sales Novo NordiskIn the last report, the company increased weight loss medication, which broke box office records in the second quarter, after cutting full -year guidance and announced a new CEO.
Total revenues rose to the Danish crown ($ 11.92 billion) 76.86 billion in three months in front of 76.6 billion Danish crowner estimates by the end of June, 76.86 billion in three months ($ 11.92 billion).
Wegovy obesity medication, which broke box office records, increased by 67% during the sales period and rose to 19.53 billion Danish Kroner, which was estimated by 20 billion Danish Kron analysts.
The three -month net profit came to 26.5 billion Danish Kroner and 26.6 billion Danish chronic analyst was expected.
This is an developing story. Please check again for updates.
